研報掘金丨華福證券:維持健友股份“買入”評級,25Q1短期波動不改長期增長本色
華福證券研報指出,健友股份(603707.SH)2024年實現歸母淨利潤8.26億元,同比增加536.09%;25Q1實現歸母淨利潤0.85億元,同比減少52.19%。24年業績符合預期,25Q1短期波動不改長期增長本色。近年來公司積極尋求外部合作,先後與海南雙成、通化東寶達成戰略合作,取得白蛋白紫杉醇、甘精、門冬、賴脯三種胰島素在美國市場的獨家商業化權益,未來隨着生物類似藥在美國市場獲批,有望助力海外製劑業務快速放量。考慮到公司作爲快速轉型中的肝素原料藥企業,海外注射製劑的快速增長以及生物類似藥出海有望爲25-26年業績貢獻顯著增量,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.